Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$225.30 USD

225.30
2,859,201

-2.66 (-1.17%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $225.11 -0.19 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw

by Zacks Equity Research

Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.

Chemed (CHE) Q4 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.

Cencora (COR) Is Up 2.40% in One Week: What You Should Know

by Zacks Equity Research

Does Cencora (COR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Philips' (PHG) New Innovation to Boost Neurovascular Diagnosis

by Zacks Equity Research

Philips (PHG) announces its latest Azurion neuro biplane system, which aims to improve the diagnosis of stroke and major neurovascular diseases. The system is designed for superior patient care.

Patterson Companies (PDCO) Misses on Q3 Earnings, Lowers EPS View

by Zacks Equity Research

Patterson Companies' (PDCO) third-quarter fiscal 2024 results reflect an improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales appear weak.

Inogen (INGN) Q4 Earnings Miss Estimates, Gross Margin Improves

by Zacks Equity Research

Inogen's (INGN) fourth-quarter earnings and revenues miss their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Masimo (MASI) Q4 Earnings Beat Estimates, Margins Decline

by Zacks Equity Research

Despite strength in the Hearables category, Masimo's (MASI) overall fourth-quarter results reflect soft performances.

OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.

Insulet (PODD) Q4 Earnings, Revenues Top Mark, Margins Expand

by Zacks Equity Research

In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.

Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down

by Zacks Equity Research

Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.

Alcon (ALC) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Alcon (ALC) delivers impressive performance across its franchises in the fourth quarter of 2023.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.

Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity

by Zacks Equity Research

Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.

GE HealthCare (GEHC), Biofourmis Partner to Boost At-Home Care

by Zacks Equity Research

GE HealthCare (GEHC) collaborates with Biofourmis to facilitate the patient's journey throughout the healthcare system and make the transition from hospital to home care easier.

Humana (HUM) Collaborates With Veda to Enhance Efficiency

by Zacks Equity Research

Humana (HUM) partners with Veda to enhance the quality of provider directories.

Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Henry Schein (HSIC) Q4 Earnings Miss, Operating Margin Down

by Zacks Equity Research

Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

by Zacks Equity Research

Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.

Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Philips' (PHG) New Innovation to Boost Radiation-Free Imaging

by Zacks Equity Research

Philips (PHG) announces its latest LumiGuide imaging technology, which is likely to pave the way for new radiation-free procedures. It will prove beneficial for complex aortic surgeries.

Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEV

HCA Healthcare (HCA) Drives Efficiency With New Outpatient Model

by Zacks Equity Research

HCA Healthcare's (HCA) Sarah Cannon Cancer Institute adopts a new outpatient model for CAR T-cell therapy patients.

Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up

by Zacks Equity Research

The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.

BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening

by Zacks Equity Research

BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.